Neopharmed Gentili executed agreement to acquire the metoclopramide product portfolio to strengthen its gastrointestinal division
- Neopharmed Gentili enters into purchase agreement to acquire rights in Italy and 14 other countries internationally to the established brands Plasil® and Primperan®.
- The transaction will allow Neopharmed Gentili to strengthen its portfolio in the gastrointestinal area with high value-added antiemetic drugs.
Milan, February 04, 2025 – Neopharmed Gentili, an Italian pharmaceutical company controlled by Ardian and NB Renaissance in partnership with the Del Bono family, which has historic roots in its territory and is pursuing international growth, announced that it has entered into an agreement with Sanofi for the acquisition of the rights in Italy and 14 other countries internationally to the Plasil® and Primperan® brands. Metoclopramide products are indicated in the prevention of nausea and vomiting.
The agreement is the result of a close collaboration with Sanofi, which will also ensure a smooth post-closing transition of the assets in the 15 countries without disruption in the market. Closing is subject to customary conditions.
The transaction confirms the company’s strong growth momentum thanks to its consolidated experience in M&A and licensing transactions, especially with multinational partners.
***
About Neopharmed Gentili
Neopharmed Gentili is a pharmaceutical company founded in Italy with historic roots in its territory, which is rapidly expanding beyond national borders thanks to a consolidated and reliable experience in M&A and Licensing transactions, especially with multinational partners. Research, responsibility and care are the pillars that guide Neopharmed Gentili’s mission to improve the health and quality of life of patients, caregivers and healthcare personnel. Neopharmed Gentili’s ambition is to help people live long and healthy lives, acting with ethical value and scientific precision, and offering solutions with high therapeutic value.
***
For further information:
Neopharmed Gentili press office
Value Relations
Angela Del Giudice Mob. +39 392.6858392 | a.delgiudice@vrelations.it
Chiara Farroni Mob. +39 331.4997375 | c.farroni@vrelations.it
